These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29435178)

  • 21. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer.
    Pettazzoni P; Viale A; Shah P; Carugo A; Ying H; Wang H; Genovese G; Seth S; Minelli R; Green T; Huang-Hobbs E; Corti D; Sanchez N; Nezi L; Marchesini M; Kapoor A; Yao W; Francesco ME; Petrocchi A; Deem AK; Scott K; Colla S; Mills GB; Fleming JB; Heffernan TP; Jones P; Toniatti C; DePinho RA; Draetta GF
    Cancer Res; 2015 Mar; 75(6):1091-101. PubMed ID: 25736685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trametinib Potentiates Anti-PD-1 Efficacy in Tumors Established from Chemotherapy-Primed Pancreatic Cancer Cells.
    Pham TD; Metropulos AE; Mubin N; Becker JH; Shah D; Spaulding C; Shields MA; Bentrem DJ; Munshi HG
    Mol Cancer Ther; 2024 Dec; 23(12):1854-1865. PubMed ID: 39162011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition.
    MacKeigan JP; Taxman DJ; Hunter D; Earp HS; Graves LM; Ting JP
    Clin Cancer Res; 2002 Jul; 8(7):2091-9. PubMed ID: 12114408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
    Gysin S; Lee SH; Dean NM; McMahon M
    Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration.
    Giehl K; Skripczynski B; Mansard A; Menke A; Gierschik P
    Oncogene; 2000 Jun; 19(25):2930-42. PubMed ID: 10871844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth.
    Khan HY; Mpilla GB; Sexton R; Viswanadha S; Penmetsa KV; Aboukameel A; Diab M; Kamgar M; Al-Hallak MN; Szlaczky M; Tesfaye A; Kim S; Philip PA; Mohammad RM; Azmi AS
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32235707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma.
    Stauffer S; Roth JS; Hernandez ER; Kowalczyk JT; Sealover NE; Hebron KE; James A; Isanogle KA; Riffle LA; Ileva L; Luo X; Chen JQ; Kedei N; Kortum RL; Lei H; Shern JF; Kalen JD; Edmondson EF; Hall MD; Difilippantonio S; Thiele CJ; Yohe ME
    Cancers (Basel); 2024 Jun; 16(13):. PubMed ID: 39001383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A case of class 3
    Wang C; Sandhu J; Fakih M
    J Gastrointest Oncol; 2019 Dec; 10(6):1140-1143. PubMed ID: 31949931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors.
    Zhang L; Marrano P; Kumar S; Leadley M; Elias E; Thorner P; Baruchel S
    Clin Cancer Res; 2013 Nov; 19(21):5972-83. PubMed ID: 23989978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
    Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
    Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pancreatic Cancer Treatment Targeting the HGF/c-MET Pathway: The MEK Inhibitor Trametinib.
    Kim J; Lee TS; Lee MH; Cho IR; Ryu JK; Kim YT; Lee SH; Paik WH
    Cancers (Basel); 2024 Mar; 16(5):. PubMed ID: 38473413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.
    Zhao C; Xiao H; Wu X; Li C; Liang G; Yang S; Lin J
    Oncotarget; 2015 Jun; 6(16):14472-87. PubMed ID: 25961376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy.
    Awasthi N; Schwarz MA; Schwarz RE
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):571-82. PubMed ID: 21110024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer.
    Ball DW; Jin N; Xue P; Bhan S; Ahmed SR; Rosen DM; Schayowitz A; Clark DP; Nelkin BD
    Oncol Rep; 2015 Nov; 34(5):2319-24. PubMed ID: 26324075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transforming growth factor β and Ras/MEK/ERK signaling regulate the expression level of a novel tumor suppressor Lefty.
    Miyata N; Azuma T; Hozawa S; Higuchi H; Yokoyama A; Kabashima A; Igarashi T; Saeki K; Hibi T
    Pancreas; 2012 Jul; 41(5):745-52. PubMed ID: 22441145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Semaphorin 3 C enhances putative cancer stemness and accelerates peritoneal dissemination in pancreatic cancer.
    Tomizawa S; Takano S; Eto R; Takayashiki T; Kuboki S; Ohtsuka M
    Cancer Cell Int; 2023 Aug; 23(1):155. PubMed ID: 37537633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the IκB Kinase Enhancer and Its Feedback Circuit in Pancreatic Cancer.
    Challa S; Husain K; Kim R; Coppola D; Batra SK; Cheng JQ; Malafa MP
    Transl Oncol; 2020 Feb; 13(2):481-489. PubMed ID: 32004866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fibroblast inhibition by tocilizumab enabled gemcitabine/nab-paclitaxel rechallenge for pancreatic cancer.
    Mitsunaga S; Ikeda M; Imaoka H; Sasaki M; Watanabe K; Sato A; Aoki K; Ochiai A; Makikawa M; Nishidate M; Yamaguchi K; Terao K; Sawada N; Fujitomo T; Fujii E; Kato A; Tsunoda H
    Cancer Sci; 2023 Oct; 114(10):4006-4019. PubMed ID: 37605479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MEK blockade overcomes the limited activity of palbociclib in head and neck cancer.
    Fang Z; Jung KH; Lee JE; Cho J; Lim JH; Hong SS
    Transl Oncol; 2020 Nov; 13(11):100833. PubMed ID: 32712554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gemcitabine elaidate and ONC201 combination therapy for inhibiting pancreatic cancer in a KRAS mutated syngeneic mouse model.
    Kumar V; Sethi B; Staller DW; Shrestha P; Mahato RI
    Cell Death Discov; 2024 Mar; 10(1):158. PubMed ID: 38553450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.